Daewoong Pharmaceutical Launches Botulinum Toxin NUCEIVA in Spain

COMPANY / Reporter Kim Jisun / 2024-06-20 01:58:03

Daewoong Pharmaceutical

 

[Alpha Biz= Reporter Kim Jisun] Daewoong Pharmaceutical announced on the 19th that it will launch its botulinum toxin 'NUCEIVA' in Spain through its partner 'Evolus'.

With this, Daewoong Pharmaceutical's botulinum toxin has expanded its presence in Europe to a total of five countries: the UK, Germany, Austria, Italy, and now Spain. Europe is the second-largest botulinum toxin market after the United States.

Evolus, Daewoong Pharmaceutical's partner, will handle the distribution and marketing of NUCEIVA in Spain. They plan to support the rapid market penetration of NUCEIVA by offering various training programs for local healthcare professionals and providing online platforms.

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

Hyundai Motor Securities Raises SK Hynix Target Price by 24.6% to KRW 405,000
Shinhan Investment & Securities Maintains ‘Buy’ Rating on Orion, Expects Sales Growth and Stock Recovery in Second Half
Samsung Securities Raises Target Price for L&F to KRW 100,000, Citing Stronger Fundamental Recovery
Hyundai Mobis Union Continues Strike Independently, Citing Broken Wage Agreement
Over KRW 1.5 Trillion in Pension Premiums Miscollected Over Past 5.5 Years
뉴스댓글 >

SNS